The risk of hypoglycemia is a barrier to optimal treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM), especially in the context of insulin therapy, making blood glucose control optimization challenging [13]. This evidence concerns the gene INS and Hypoglycemia.